Elanco Animal Health Inc. announced Nov. 2 a new global research and development (R&D) collaboration with Novozymes A/S, leader in biological solutions, to develop nutritional health products for beef cattle and dairy cows globally.
The effort will leverage Novozymes' discovery and development programs, and together the companies will collaborate to develop an R&D pipeline and commercialize products in the next decade, the announcement explained.
“Nutritional health is an exciting platform that will define the next generation of feed additives to improve the health and performance of food animals,” said Aaron Schacht, Elanco Animal Health executive vice president, innovation, regulatory and business development. “This collaboration expands our growing nutritional health capability into cattle and underscores Elanco's commitment to bring producers innovative alternatives to antibiotics while preserving the health and welfare of the animal.”
Identifying and developing new products and tools to help manage the animal's microbiome, control infections and reduce gut inflammation while decreasing the need for medically important antibiotics is a top priority for Elanco.
“We are excited to collaborate with Elanco to develop nutritional health products for dairy cows and beef cattle production that can improve sustainability in the industry,” said Susanne Palsten Buchardt, Novozymes vice president, animal health and nutrition. “The collaboration is an important step in our efforts to deliver sustainable solutions for better lives in a growing world.”
Applying new biological and sustainable tools for animal health and nutrition in cattle production is more challenging due to the animals' complicated digestive systems, longer lives and less-integrated production with significantly more commingling of animals. Partnering the complementary capabilities of Elanco and Novozymes, from research to commercialization, will further advance these efforts.
As part of its eight-point Antibiotic Stewardship Plan released in 2015, Elanco aims to deliver a total of 25 viable antibiotic alternative development projects by 2020 that address critical unmet challenges in livestock production and reduce the need for shared‐class antibiotics that are also critical to human medicine, the announcement said. To date, Elanco said it has identified and added 16 alternative development projects to its pipeline.
Founded in 1954 and headquartered in Greenfield, Ind., Elanco provides comprehensive products and knowledge services to improve animal health and food animal production in more than 90 countries. The company is committed to raising awareness about global food security and celebrating and supporting the human/animal bond.
Novozymes is the world's largest provider of enzyme and microbial technologies that enable higher agricultural yields, low-temperature washing, energy-efficient production, renewable fuel and other benefits. Together with customers, partners and the global community, Novozymes strives to improve industrial performance while preserving the planet's resources and helping build better lives.